HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.

Abstract
To increase our understanding of the effect of thiazolidinediones, a new class of antidiabetic drugs, on liver function as well as glycemic control, we investigated liver function before, during, and after treatment with troglitazone and pioglitazone. A total of 32 patients with type 2 diabetes were studied. Glycemic control and liver function were measured before, during, and after 4 to 12 weeks of treatment with troglitazone or pioglitazone. Glycemic control was assessed by fasting levels of plasma glucose, hemoglobin A 1c , and serum insulin, and liver function was assessed by asparatate aminotransferase (AST), alanine aminotransferase (ALT), and gamma -glutamyl transpeptidase ( gamma-GTP). Homeostasis model assessment for insulin resistance was used as an index of insulin resistance. During treatment with troglitazone, fasting plasma glucose and hemoglobin A 1c levels and homeostasis model assessment for insulin resistance were significantly decreased. Serum AST, ALT, and gamma-GTP levels were significantly decreased during treatment (AST, -17.4%; ALT, -27.2%; gamma-GTP, -47.9%) and returned to pretreatment levels after 4 weeks of withdrawal of the drug. A similar tendency was observed during treatment with pioglitazone (AST, -4.7%; ALT, -16.4%; gamma-GTP, -30.8%). These data suggest that, in contrast to the deterioration of liver function reported in a small subset of patients treated with troglitazone, treatment with thiazolidinediones was associated with a decrease in serum transaminases in most patients. The improvement in liver function parameters known to be associated with fatty liver in the present study, together with an improvement in fatty liver reported for another class of insulin sensitizers, biguanides, suggests that thiazolidinediones may have a beneficial effect on fatty liver.
AuthorsMasaya Ono, Hiroshi Ikegami, Tomomi Fujisawa, Koji Nojima, Yumiko Kawabata, Masanori Nishino, Hidenori Taniguchi, Michiko Itoi-Babaya, Naru Babaya, Kaori Inoue, Toshio Ogihara
JournalMetabolism: clinical and experimental (Metabolism) Vol. 54 Issue 4 Pg. 529-32 (Apr 2005) ISSN: 0026-0495 [Print] United States
PMID15798962 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Glucose
  • Chromans
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Thiazolidinediones
  • gamma-Glutamyltransferase
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Troglitazone
  • Pioglitazone
Topics
  • Alanine Transaminase (blood)
  • Aspartate Aminotransferases (blood)
  • Blood Glucose (analysis)
  • Chromans (therapeutic use)
  • Diabetes Mellitus, Type 2 (drug therapy, physiopathology)
  • Glycated Hemoglobin (analysis)
  • Homeostasis
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Insulin (blood)
  • Insulin Resistance
  • Liver (physiopathology)
  • Pioglitazone
  • Thiazolidinediones (therapeutic use)
  • Troglitazone
  • gamma-Glutamyltransferase (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: